Gufic Biosciences (509079) Q4 24/25 earnings summary

Executive summary

• Focused on targeted execution, realigned sales teams, and expanded KOL partnerships to drive growth in critical care, fertility, aesthetics, and neuro care segments.

• Launched new products (Eclin, IVIG, contrast media), expanded international presence with new distribution agreements, and strategic leadership appointments.

• Indore facility ramp-up and commercialization delayed for regulatory compliance, impacting short-term profitability but expected to be margin-accretive by FY27.

• Strong R&D pipeline, new partnerships, and focus on regulated markets underpin long-term growth.

• Audited standalone and consolidated financial results for FY25 were approved with an unmodified opinion; final dividend of 10% recommended.

Financial highlights

• Q4 FY25 revenue at Rs 205 crore, up from Rs 195 crore in Q4 FY24; full-year FY25 revenue at Rs 819.8 crore, up from Rs 806.7 crore.

• Q4 FY25 EBITDA at Rs 27 crore (13.16% margin), down from Rs 35.1 crore (18%) in Q4 FY24; FY25 EBITDA at Rs 138.6 crore (FY24: Rs 148 crore).

• Q4 FY25 PAT at Rs 8 crore (3.9% margin), down from Rs 20 crore (10.26%) in Q4 FY24; FY25 PAT at Rs 69.9 crore (FY24: Rs 86.2 crore).

• Net cash from operating activities in FY25 was Rs 122.8 crore, a significant improvement from negative Rs 7.5 crore in FY24.

• Basic and diluted EPS for FY25 were Rs 6.95, down from Rs 8.74 in FY24.

Outlook and guidance

• Indore facility expected to reach EBITDA break-even in FY26 and become margin-accretive by FY27.

• International business targeted to grow from 16-18% to 25% of total revenue in 2-3 years, with export revenue expected to 1.5x-2x in 3-5 years.

• Botulinum toxin revenue projected to reach Rs 100 crore in 3 years, with market share goals of 20-22% in aesthetics and 25-26% in neurology.

• Board recommended a final dividend and approved further investments in subsidiaries to expand international presence.